This is a Phase 1 study during which patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) will receive investigational study drug ARRY-614. This study has 2 parts. In the first part, patients will receive increasing doses of study drug, given either with food or without food, in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Approximately 60 patients from the US will be enrolled in Part 1 (Completed). In the second part of this study, patients will receive the best dose of study drug, given either with food or without food, determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 40 patients from the US will be enrolled in Part 2 (Completed).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Moffitt Cancer Center
Tampa, Florida, United States
Winship Cancer Institute
Atlanta, Georgia, United States
MD Anderson Cancer Center
Houston, Texas, United States
Characterize the safety profile of the study drug, in either the fasted or fed state, in terms of adverse events, clinical laboratory tests and electrocardiograms.
Time frame: Part 1, one year; Part 2, one year
Establish the maximum tolerated dose (MTD) of the study drug.
Time frame: Part 1, one year
Characterize the pharmacokinetics of the study drug and a metabolite under either fasted or fed conditions.
Time frame: Part 1, one year; Part 2, one year
Assess the efficacy of study drug in terms of response, duration of response and hematologic improvement.
Time frame: Part 1, one year; Part 2, one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.